Krishnankutty Sudhir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Krishnankutty Sudhir has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra J. Lansky
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
7 shared publications James B. Hermiller
The Care Group, LLC, St. Vincent Heart Center of Indiana, Indianapolis, IN 46290, USA
5 shared publicationsCharles A. Simonton
Abbott Vascular, Santa Clara, USA
4 shared publications- Gregg Whitney Stone
Icahn School of Medicine at Mount Sinai , New York, NY
4 shared publications Poornima Sood
Abbott Vascular, Santa Clara, California
4 shared publications- Manejeh Yaqub
Genentech, Inc., A Member of the Roche Group, South San Francisco, USA
3 shared publications
Latest Publications
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 222, 832-840
Current practices of Asia-Pacific cardiologists in the utilization of bioresorbable scaffolds
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 222, 832-840
Current practices of Asia-Pacific cardiologists in the utilization of bioresorbable scaffolds
- 1 February 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (4) , S20
CRT-200.55 Outcomes After Very Long Lesion Treatment With Everolimus Eluting Stents
- 1 February 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (4) , S20
CRT-200.55 Outcomes After Very Long Lesion Treatment With Everolimus Eluting Stents
- 1 February 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (4) , S20
CRT-200.54 Evaluation of 2-year Clinical Outcomes From Post-market Trials With Everolimus-eluting Cobalt Chromium Stents in Diabetics
- 1 February 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (4) , S20
CRT-200.54 Evaluation of 2-year Clinical Outcomes From Post-market Trials With Everolimus-eluting Cobalt Chromium Stents in Diabetics
- 1 July 2013
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 9 (3) , 353-359
Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 July 2013
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 9 (3) , 353-359
Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- Open Access
- 23 June 2013
- Published by Wiley in ISRN Cardiology
- Vol. 2013, 1-8
Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy
The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. Procedural factors such as stent underexpansion and malapposition are risk factors for ST in patients. The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can contribute to ST. Second-generation DES such as the XIENCE V everolimus-eluting stent differ from the first-generation stents with respect to antiproliferative agents, coating technologies, and stent frame. Improvements in stent structure have resulted in a more complete endothelialization, thereby decreasing the incidence of ST. Bioresorbable scaffolds show promise for restoring vasomotor function and minimizing rates of very late ST. Post-PCI treatment with aspirin and clopidogrel for a year is currently the standard of care for DES, but high-risk patients may benefit from more potent antiplatelet agents. The optimal duration of DAPT for DES is currently unclear and will be addressed in large-scale randomized clinical trials.
- 23 June 2013
- Published by Wiley in ISRN Cardiology
- Vol. 2013, 1-8
Open AccessRisk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy
The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. Procedural factors such as stent underexpansion and malapposition are risk factors for ST in patients. The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can contribute to ST. Second-generation DES such as the XIENCE V everolimus-eluting stent differ from the first-generation stents with respect to antiproliferative agents, coating technologies, and stent frame. Improvements in stent structure have resulted in a more complete endothelialization, thereby decreasing the incidence of ST. Bioresorbable scaffolds show promise for restoring vasomotor function and minimizing rates of very late ST. Post-PCI treatment with aspirin and clopidogrel for a year is currently the standard of care for DES, but high-risk patients may benefit from more potent antiplatelet agents. The optimal duration of DAPT for DES is currently unclear and will be addressed in large-scale randomized clinical trials.
- 28 March 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 82 (4) , E385-E394
Clinical outcomes in real‐world patients with acute myocardial infarction receiving XIENCE V® everolimus‐eluting stents
Objectives: The objective of this analysis was to evaluate the safety and effectiveness of XIENCE V in acute myocardial infarction (AMI).Background: The XIENCE V® Everolimus‐eluting coronary stent was superior to the TAXUS® paclitaxel‐eluting stent in angiographic and clinical outcomes in the SPIRIT II, III, and IV randomized controlled trials, but patients with AMI were excluded.Methods: XIENCE V USA is a large, prospective, multicenter, real‐world single‐arm postmarket surveillance trial. Consecutive patients undergoing PCI with XIENCE V were enrolled. For this analysis, clinical outcomes in 673 patients presenting with AMI (STEMI, n = 125) were as compared to patients without AMI (n = 3528) at 1 year.Results: At 1 year, ARC‐defined stent thrombosis (ST) rates were 1.08% in AMI vs. 0.85% in the non‐AMI group (P = 0.4987). The late ST (30 days‐1 year) rates were 0.31% vs. 0.47% (AMI vs. non‐AMI, P = 0.7551). Rates of target lesion revascularization (TLR) were 4.1% vs. 4.6% (P = 0.6104), and rates of target lesion failure (TLF) were 9.1% vs. 8.5%, (P = 0.5964). With the historical WHO definition of MI, 1 year TLF rates were 7.0% vs. 6.7% (P = 0.8001). Improvements in quality of life, angina frequency, angina stability, and physical limitations occurred at 6 months (each P < 0.0001) and were sustained at 1 year in both groups. There were no significant differences in clinical outcomes between STEMI and non‐STEMI patients.Conclusions: At 1 year, AMI patients treated with XIENCE V had low rates of ST, TLR, and TLF, similar to non‐AMI patients. Marked improvements in patients' health status in this subgroup were also demonstrated.
- 28 March 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 82 (4) , E385-E394
Clinical outcomes in real‐world patients with acute myocardial infarction receiving XIENCE V® everolimus‐eluting stents
Objectives: The objective of this analysis was to evaluate the safety and effectiveness of XIENCE V in acute myocardial infarction (AMI).Background: The XIENCE V® Everolimus‐eluting coronary stent was superior to the TAXUS® paclitaxel‐eluting stent in angiographic and clinical outcomes in the SPIRIT II, III, and IV randomized controlled trials, but patients with AMI were excluded.Methods: XIENCE V USA is a large, prospective, multicenter, real‐world single‐arm postmarket surveillance trial. Consecutive patients undergoing PCI with XIENCE V were enrolled. For this analysis, clinical outcomes in 673 patients presenting with AMI (STEMI, n = 125) were as compared to patients without AMI (n = 3528) at 1 year.Results: At 1 year, ARC‐defined stent thrombosis (ST) rates were 1.08% in AMI vs. 0.85% in the non‐AMI group (P = 0.4987). The late ST (30 days‐1 year) rates were 0.31% vs. 0.47% (AMI vs. non‐AMI, P = 0.7551). Rates of target lesion revascularization (TLR) were 4.1% vs. 4.6% (P = 0.6104), and rates of target lesion failure (TLF) were 9.1% vs. 8.5%, (P = 0.5964). With the historical WHO definition of MI, 1 year TLF rates were 7.0% vs. 6.7% (P = 0.8001). Improvements in quality of life, angina frequency, angina stability, and physical limitations occurred at 6 months (each P < 0.0001) and were sustained at 1 year in both groups. There were no significant differences in clinical outcomes between STEMI and non‐STEMI patients.Conclusions: At 1 year, AMI patients treated with XIENCE V had low rates of ST, TLR, and TLF, similar to non‐AMI patients. Marked improvements in patients' health status in this subgroup were also demonstrated.
- 1 July 2012
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 8 (3) , 325-335
SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 July 2012
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 8 (3) , 325-335
SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 July 2011
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 7 (3) , 307-313
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 July 2011
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 7 (3) , 307-313
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 March 2011
- Published by Elsevier in The American Journal of Cardiology
- Vol. 107 (6) , 841-848
Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)
- 1 March 2011
- Published by Elsevier in The American Journal of Cardiology
- Vol. 107 (6) , 841-848
Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)